Journal article
Nanoparticle Ligand Presentation for Targeting Solid Tumors
AAPS PharmSciTech, Vol.15(5), pp.1345-1354
10/2014
DOI: 10.1208/s12249-014-0143-6
PMCID: PMC4179653
PMID: 24927668
Abstract
Among the many scientific advances to come from the study of nanoscience, the development of ligand-targeted nanoparticles to eliminate solid tumors is predicted to have a major impact on human health. There are many reports describing novel designs and testing of targeted nanoparticles to treat cancer. While the principles of the technology are well demonstrated in controlled lab experiments, there are still many hurdles to overcome for the science to mature into truly efficacious targeted nanoparticles that join the arsenal of agents currently used to treat cancer in humans. One of these hurdles is overcoming unwanted biodistribution to the liver while maximizing delivery to the tumor. This almost certainly requires advances in both nanoparticle stealth technology and targeting. Currently, it continues to be a challenge to control the loading of ligands onto polyethylene glycol (PEG) to achieve maximal targeting. Nanoparticle cellular uptake and subcellular targeting of genes and siRNA also remain a challenge. This review examines the types of ligands that have been most often used to target nanoparticles to solid tumors. As the science matures over the coming decade, careful control over ligand presentation on nanoparticles of precise size, shape, and charge will likely play a major role in achieving success.
Details
- Title: Subtitle
- Nanoparticle Ligand Presentation for Targeting Solid Tumors
- Creators
- Jason T Duskey - Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242 USAKevin G Rice - Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242 USA
- Resource Type
- Journal article
- Publication Details
- AAPS PharmSciTech, Vol.15(5), pp.1345-1354
- DOI
- 10.1208/s12249-014-0143-6
- PMID
- 24927668
- PMCID
- PMC4179653
- NLM abbreviation
- Int J Emerg Med
- ISSN
- 1865-1372
- eISSN
- 1530-9932
- Publisher
- Springer US; New York
- Language
- English
- Date published
- 10/2014
- Academic Unit
- Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Medicinal and Natural Products Chemistry
- Record Identifier
- 9984065325102771
Metrics
20 Record Views